2pmw: Difference between revisions

Line 4:

==Overview==

Proprotein convertase subtilisin kexin type 9 (PCSK9) has been shown to be, involved in the regulation of extracellular levels of the low-density, lipoprotien receptor (LDLR). Although PCSK9 is a subtilase, it has not, been shown to degrade the LDLR, and its LDLR-lowering mechanism remains, uncertain. Here we report the crystal structure of human PCSK9 at 2.3 A, resolution. PCSK9 has subtilisin-like pro- and catalytic domains, and the, stable interaction between these domains prevents access to PCSK9's, catalytic site. The C-terminal domain of PCSK9 has a novel protein fold, and may mediate protein-protein interactions. The structure of PCSK9, provides insight into its biochemical characteristics and biological, function.

Proprotein convertase subtilisin kexin type 9 (PCSK9) has been shown to be involved in the regulation of extracellular levels of the low-density lipoprotien receptor (LDLR). Although PCSK9 is a subtilase, it has not been shown to degrade the LDLR, and its LDLR-lowering mechanism remains uncertain. Here we report the crystal structure of human PCSK9 at 2.3 A resolution. PCSK9 has subtilisin-like pro- and catalytic domains, and the stable interaction between these domains prevents access to PCSK9's catalytic site. The C-terminal domain of PCSK9 has a novel protein fold and may mediate protein-protein interactions. The structure of PCSK9 provides insight into its biochemical characteristics and biological function.

==About this Structure==

Line 10:

==Reference==

The ~~Crystal Structure~~ of PCSK9: ~~A Regulator~~ of ~~Plasma~~ LDL-~~Cholesterol~~., Piper DE, Jackson S, Liu Q, Romanow WG, Shetterly S, Thibault ST, Shan B, Walker NP, Structure. 2007 May;15(5):545-52. PMID:[http://ispc.weizmann.ac.il//pmbin/getpm?pmid=17502100 17502100]

The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol., Piper DE, Jackson S, Liu Q, Romanow WG, Shetterly S, Thibault ST, Shan B, Walker NP, Structure. 2007 May;15(5):545-52. PMID:[http://ispc.weizmann.ac.il//pmbin/getpm?pmid=17502100 17502100]

[[Category: Homo sapiens]]

[[Category: Protein complex]]

[[Category: Piper, D.E.]]

[[Category: Piper, D E.]]

[[Category: Romanow, W.G.]]

[[Category: Romanow, W G.]]

[[Category: Thibault, S.T.]]

[[Category: Thibault, S T.]]

[[Category: Walker, N.P.C.]]

[[Category: Walker, N P.C.]]

[[Category: SO4]]

[[Category: propeptide]]

Line 22:

[[Category: subtilisin]]

''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on ~~Wed Jan 23 15~~:09~~:50~~ 2008''

''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 18:31:09 2008''

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

@@ Line 4: / Line 4: @@
 ==Overview==
-Proprotein convertase subtilisin kexin type 9 (PCSK9) has been shown to be, involved in the regulation of extracellular levels of the low-density, lipoprotien receptor (LDLR). Although PCSK9 is a subtilase, it has not, been shown to degrade the LDLR, and its LDLR-lowering mechanism remains, uncertain. Here we report the crystal structure of human PCSK9 at 2.3 A, resolution. PCSK9 has subtilisin-like pro- and catalytic domains, and the, stable interaction between these domains prevents access to PCSK9's, catalytic site. The C-terminal domain of PCSK9 has a novel protein fold, and may mediate protein-protein interactions. The structure of PCSK9, provides insight into its biochemical characteristics and biological, function.
+Proprotein convertase subtilisin kexin type 9 (PCSK9) has been shown to be involved in the regulation of extracellular levels of the low-density lipoprotien receptor (LDLR). Although PCSK9 is a subtilase, it has not been shown to degrade the LDLR, and its LDLR-lowering mechanism remains uncertain. Here we report the crystal structure of human PCSK9 at 2.3 A resolution. PCSK9 has subtilisin-like pro- and catalytic domains, and the stable interaction between these domains prevents access to PCSK9's catalytic site. The C-terminal domain of PCSK9 has a novel protein fold and may mediate protein-protein interactions. The structure of PCSK9 provides insight into its biochemical characteristics and biological function.
 ==About this Structure==
@@ Line 10: / Line 10: @@
 ==Reference==
-The Crystal Structure of PCSK9: A Regulator of Plasma LDL-Cholesterol., Piper DE, Jackson S, Liu Q, Romanow WG, Shetterly S, Thibault ST, Shan B, Walker NP, Structure. 2007 May;15(5):545-52. PMID:[http://ispc.weizmann.ac.il//pmbin/getpm?pmid=17502100 17502100]
+The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol., Piper DE, Jackson S, Liu Q, Romanow WG, Shetterly S, Thibault ST, Shan B, Walker NP, Structure. 2007 May;15(5):545-52. PMID:[http://ispc.weizmann.ac.il//pmbin/getpm?pmid=17502100 17502100]
 [[Category: Homo sapiens]]
 [[Category: Protein complex]]
-[[Category: Piper, D.E.]]
+[[Category: Piper, D E.]]
-[[Category: Romanow, W.G.]]
+[[Category: Romanow, W G.]]
-[[Category: Thibault, S.T.]]
+[[Category: Thibault, S T.]]
-[[Category: Walker, N.P.C.]]
+[[Category: Walker, N P.C.]]
 [[Category: SO4]]
 [[Category: propeptide]]
@@ Line 22: / Line 22: @@
 [[Category: subtilisin]]
-''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Jan 23 15:09:50 2008''
+''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 18:31:09 2008''